Vaccination therapy for Alzheimer's disease

Brain and Nerve

Volumn 59, Issue 4, 2007, Pages 375-382

  Tabira, Takeshi ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

AAV vector; Amyloid; Immune response; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; ARTICLE; AUTOIMMUNITY; CLINICAL TRIAL; COGNITION; DEGENERATIVE DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; MENINGOENCEPHALITIS; NONHUMAN; VACCINATION;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; ANIMALS; HAPLORHINI; HUMANS; MICE; SENILE PLAQUES;

EID: 34247339327     PISSN: 00068969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177, 1999
2. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919, 2000
3. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982, 2000
4. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985, 2000
5. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54, 2003
6. Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, et al: Abeta-induced meningoencephalitis is IFN-gamma- dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A103: 5048-5053, 2006
7. Monsonego A, Zota V, Kami A, Krieger JI, Bar-Or A, et al: Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112: 415-422, 2003
8. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452, 2003
9. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, et al: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38: 547-554, 2003
10. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562, 2005
11. Hara H, Monsonego A, Yuasa K, Adachi K, Xiao X, et al: Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheim Dis 6: 483-488, 2004
12. Frenkel D, Maron R, Burt DS, Weiner HL: Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 115: 2423-2433, 2005
13. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, et al: Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A 103: 11784-11789, 2006
14. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S: Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49: 489-502, 2006
15. Akiyama H, McGeer PL: Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med 10:117-118, 2004